Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Liabilities from Discontinued Operations (2021 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Liabilities from Discontinued Operations for 2 consecutive years, with 35692000.0 as the latest value for Q2 2025.

  • Quarterly Liabilities from Discontinued Operations changed N/A to 35692000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 35692000.0 through Jun 2025, changed N/A year-over-year, with the annual reading at 13566000.0 for FY2021, N/A changed from the prior year.
  • Liabilities from Discontinued Operations hit 35692000.0 in Q2 2025 for Ligand Pharmaceuticals, up from 25509000.0 in the prior quarter.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 35692000.0 in Q2 2025 to a low of 13566000.0 in Q4 2021.